about
Cellular immune responses against hepatitis C virus: the evidence base 2002Temporal Dynamics of a Predominant Protease Inhibitor–Resistance Mutation in a Treatment-Naive, Hepatitis C Virus–Infected IndividualHepatitis C virus infectionThe broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine designAntibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil.Hurdles to the Development of Effective HBV Immunotherapies and HCV VaccinesChronic HCV infection affects the NK cell phenotype in the blood more than in the liver.Rare birds in North America: acute hepatitis C cohortsGenome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis.Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitopeHuman MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cellsUnderascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review.Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative.Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccineUp-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression.Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance.Acute hepatitis C infection lowers serum lipid levelsComprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.Prospective follow-up of patients with acute hepatitis C virus infection in Brazil.Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.Hepatitis B virus infection and the immune response: The big questions.Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males.Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.Historical Trends in the Hepatitis C Virus Epidemics in North America and AustraliaCutting Edge: B Cell-Intrinsic T-bet Expression Is Required To Control Chronic Viral Infection.Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections.The epigenetic landscape of T cell exhaustion.Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140Bystander chronic infection negatively impacts development of CD8(+) T cell memory.The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection.Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.
P50
Q27480725-9947818F-899F-4134-A6F0-899FE13D65A1Q27488198-1D3FDC8E-F857-48F3-AFFE-4226F8DD8F90Q27861002-708BDACB-7915-440C-AC46-160E68BC7D6EQ28602408-D9B04184-FD8D-4B08-B944-46F9CC411326Q33791343-3A8CFCA4-CE4E-4D51-BAC0-433CDDD24917Q33840260-AE4B5B7B-A460-4C1F-8113-FC0C138C241CQ34078846-A40F435F-E8BD-41C3-BCD7-B9766F87974BQ34084126-40628A99-A865-40B8-BEB7-9BD6903C7A50Q34401717-AD687674-09E0-4C29-B7DD-19AC6BC7872BQ35404598-16C5F216-5F4C-48C8-97CF-A7EB4B15676FQ35669203-88086843-587B-4F8E-AABD-B7E8907E6A42Q36514676-68B7FA1D-63C3-4A7A-BC56-A8284805BAC8Q36670894-91153CB7-C381-4F89-A24B-26C12FC63717Q36717008-5805AB3C-C49A-456A-8C3A-265525715068Q36875670-1E17C85D-3F45-4FA9-9ECB-B8E60FA0C9DFQ37059430-6CDB4C03-7807-4291-82BE-85ED6AECC415Q37084874-5D4BCFDF-E036-45D7-A1A0-1EE7DFCE9E24Q37381208-61D512F1-8C2B-4EFA-A974-2DF03F0120ADQ37385877-01A7C55D-BF47-4E53-8CB8-53514751671EQ37460833-25267512-A174-4E3E-B838-6E6A68A19ECFQ38079810-C5164C43-167F-4FEE-B943-7EEBBBC64394Q38274458-CE7C219E-2262-46AF-B8C2-BAE8D83368F1Q38647240-F2EE947A-99C0-441A-AAF4-74AC39FADB88Q38992902-12421278-D924-43B5-A594-7D29E08B0F5CQ39212153-ACD5CE01-12CB-4525-B436-0849A5C444DBQ39221144-1FA2D571-1104-4519-B6EA-BEB9EB67CB15Q39403799-B7FD9E3F-AFFD-474E-8CCD-EFCB7D69F3BCQ39403806-24C3BBBE-0EAA-4D1B-947E-E2B180197ED1Q39588420-70140397-D787-4585-BA56-99105000082BQ40209502-77FAB4B6-764F-4648-8EDC-898470AFE223Q40241251-201FBCE4-E333-426F-BA2A-2ED86A939362Q40289858-A8759873-6D3E-4654-BDC2-D8CA61E9C08DQ40478697-419A50A7-3C98-4D1A-BC4D-77BDE7DE59D7Q40695934-EDF445DA-0DB5-43A5-B617-4C7F6DE60C50Q40962102-FFCB0BC1-433A-4174-8F07-19F1D57B20C2Q41321344-DB4ADF68-738A-436C-BC0E-18EA0097BA54Q41809254-F6D8659E-4DB9-4441-8F3C-03D3CABEE8D4Q41919161-400C318D-931B-4010-B7AD-D866D74E4727Q42981811-83FD1061-40CE-4A0A-9005-1113FD7CA9DBQ42993927-1941E1B3-6D99-4135-98CB-DFA5C72AB716
P50
description
researcher ORCID ID = 0000-0002-9792-4271
@en
name
Georg M Lauer
@ast
Georg M Lauer
@en
Georg M Lauer
@nl
type
label
Georg M Lauer
@ast
Georg M Lauer
@en
Georg M Lauer
@nl
prefLabel
Georg M Lauer
@ast
Georg M Lauer
@en
Georg M Lauer
@nl
P21
P31
P496
0000-0002-9792-4271